ORAL FORMULATION OF A-NOR-5ALPHA ANDROSTANE COMPOUND

(19)

(11)

EP 3 202 404 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 153(4) EPC

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	14.02.2018 Bulletin 2018/07

(43)	Date of publication:
	09.08.2017 Bulletin 2017/32

(21)	Application number: 15847156.5

(22)	Date of filing: 28.09.2015

(51)

International Patent Classification (IPC):

A61K 31/569^(2006.01)
A61K 47/30^(2006.01)
A61K 47/14^(2017.01)
A61P 13/08^(2006.01)
A61K 9/00^(2006.01)

A61K 47/38^(2006.01)
A61K 47/26^(2006.01)
A61P 35/00^(2006.01)
A61K 9/20^(2006.01)

(86)	International application number:
	PCT/CN2015/090951

(87)	International publication number:
	WO 2016/050193 (07.04.2016 Gazette 2016/14)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

29.09.2014 CN 201410520235

(71)	Applicant: Chen, Yajun
	Shanghai 200002 (CN)

(72)	Inventor:
	Chen, Yajun Shanghai 200002 (CN)

(74)	Representative: Di Giovine, Paolo et al
	Società Italiana Brevetti S.p.A. Piazza di Pietra, 38-39 00186 Roma 00186 Roma (IT)

(56)

References cited: :

(54)	ORAL FORMULATION OF A-NOR-5ALPHA ANDROSTANE COMPOUND

(57) An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5α-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.